MedTrace Logo

Safety and Efficacy Study of a New Treatment for Symptoms of Urinary Incontinence

NCT01340066 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 94

Last updated 2013-05-03

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine if a new drug treatment is effective for the treatment of symptoms of urinary incontinence.

Conditions

Interventions

DRUG

UISH001

sublingual dosing, 1 drop 3 times a day

DRUG

matching placebo

sublingual dosing,1 drop 3 times a day

Sponsors & Collaborators

  • Norwich Clinical Research Associates Ltd.

    collaborator OTHER

  • Beech Tree Labs, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-04-30
Primary Completion
2012-05-31
Completion
2012-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01340066 on ClinicalTrials.gov